Skip to main content

Translational Research Institute

Translational Research Institute

Clinical Trials

Showing 1-9 out of 54 results.
NCT04628481

DOMPE: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline.

Icon for trial | LDX0319 DOMPE: A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and a low residual β-cell function at baseline

This study is currently enrolling.

The purpose of this study is to check and collect data of how the body absorbs, distributes and gets rid of the study drug in the blood during the first cycle of LDX0319 study treatment. These data will help improve knowledge a ...

NCT04432090

PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

Icon for trial | PHROG: A randomized, placebo-controlled, double-blinded cross-over study of the pharmacologic action of a GPR119 agonist on glucagon counter-regulation during insulin-induced hypoglycemia in Type 1 diabetes mellitus.

This study is currently enrolling.

People with type 1 diabetes are at high risk of developing hypoglycemia because of insulin treatment and because their body is less effective at increasing the levels of sugar in their blood when it is low. In this research stu ...